Annexon Raises $100M To Push Autoimmune, Brain Therapies
Clinical-stage biopharmaceutical company Annexon said Wednesday it raised $100 million from private backers to advance its pipeline of potential therapies for autoimmune, brain and eye disorders....To view the full article, register now.
Already a subscriber? Click here to view full article